Shield Therapeutics Completes Recruitment For Feraccru Trial
LONDON (Alliance News) - Shield Therapeutics PLC said on Thursday it has completed recruitment of patients for the AEGIS-H2H Phase 3b study of oral Feraccru in subjects suffering from inflammatory Read More